{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:32:32Z","timestamp":1773495152907,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40263-025-01263-8","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:57:23Z","timestamp":1770026243000},"page":"549-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolerance and Tachyphylaxis to Medications for Attention-Deficit\/Hyperactivity Disorder (ADHD): A Systematic Review of Empirical Studies"],"prefix":"10.1007","volume":"40","author":[{"given":"Christopher","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollie","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-2494","authenticated-orcid":false,"given":"Valeria","family":"Parlatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"1263_CR1","unstructured":"World Health Organization. International classification of diseases, 11th revision (ICD-11). Geneva: WHO; 2019."},{"issue":"6","key":"1263_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942\u20138.","journal-title":"Am J Psychiatry"},{"key":"1263_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1343314","volume":"15","author":"B French","year":"2024","unstructured":"French B, Nalbant G, Wright H, Sayal K, Daley D, Groom MJ, et al. The impacts associated with having ADHD: an umbrella review. Front Psychiatry. 2024;15:1343314.","journal-title":"Front Psychiatry"},{"key":"1263_CR4","unstructured":"National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. London: NICE; 2018. NICE Guideline NG87."},{"issue":"9","key":"1263_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit\/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"key":"1263_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","volume":"128","author":"SV Faraone","year":"2021","unstructured":"Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789\u2013818.","journal-title":"Neurosci Biobehav Rev"},{"key":"1263_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083658","volume":"390","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhu N, Sj\u00f6lander A, Nourredine M, Li L, Garcia-Argibay M, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ. 2025;390:e083658.","journal-title":"BMJ"},{"issue":"2","key":"1263_CR8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-069093","volume":"155","author":"S Weas","year":"2025","unstructured":"Weas S, Barbaresi WJ. ADHD prescription patterns: paying attention to trends. Pediatrics. 2025;155(2):e2024069093.","journal-title":"Pediatrics"},{"issue":"2","key":"1263_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","volume":"179","author":"MH Sibley","year":"2022","unstructured":"Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens EB, et al. Variable patterns of remission from ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry. 2022;179(2):142\u201351.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1263_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1176\/appi.ps.53.1.102","volume":"53","author":"DC Ross","year":"2002","unstructured":"Ross DC, Fischhoff J, Davenport B. Treatment of ADHD when tolerance to methylphenidate develops. Psychiatr Serv. 2002;53(1):102.","journal-title":"Psychiatr Serv"},{"key":"1263_CR11","unstructured":"Nye J. A fifth of young patients with ADHD take tolerance breaks from their medication. Psychiatry Advisor. 2023. Available from: https:\/\/www.psychiatryadvisor.com. Accessed 20 Oct 2025."},{"issue":"3","key":"1263_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0009-9236(99)70038-X","volume":"66","author":"JM Swanson","year":"1999","unstructured":"Swanson JM, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther. 1999;66(3):295\u2013305.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1263_CR13","first-page":"129","volume":"48","author":"G Katz","year":"2011","unstructured":"Katz G, Knobler HY, Laibel Z, Strauss Z, Durst R. Tachyphylaxis\/tolerance to antidepressive medications: a review. Isr J Psychiatry Relat Sci. 2011;48(2):129\u201335.","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"9","key":"1263_CR14","first-page":"537","volume":"66","author":"W Portz\u01f5en","year":"2024","unstructured":"Portz\u01f5en W, Batelaan NM, van Bergen AH, Vinkers CH, van Balkom AJ. The same agent, no response upon restart: tachyphylaxis with psychotropic medications. Tijdschr Psychiatr. 2024;66(9):537\u201343.","journal-title":"Tijdschr Psychiatr"},{"issue":"2","key":"1263_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/archpsyc.60.2.204","volume":"60","author":"JM Swanson","year":"2003","unstructured":"Swanson JM, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit\/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60(2):204\u201311.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"1263_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12080959","volume":"12","author":"KB Handelman","year":"2022","unstructured":"Handelman KB, Sumiya F. Tolerance to stimulant medication for ADHD: literature review and case report. Brain Sci. 2022;12(8):959.","journal-title":"Brain Sci"},{"key":"1263_CR17","doi-asserted-by":"crossref","unstructured":"Sridharan K, Joseph J. Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis. Eur J Hosp Pharm. 2025. [online ahead of print].","DOI":"10.1136\/ejhpharm-2024-004353"},{"issue":"9","key":"1263_CR18","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/10870547231167562","volume":"27","author":"L Barnard-Brak","year":"2023","unstructured":"Barnard-Brak L, Marques A, Kudesey C. Medication non-adherence and tolerance breaks among adolescents and young adults with ADHD. J Atten Disord. 2023;27(9):1020\u20136.","journal-title":"J Atten Disord"},{"issue":"9","key":"1263_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1176\/appi.ajp.2019.18111296","volume":"176","author":"AFM Matthijssen","year":"2019","unstructured":"Matthijssen AFM, Hezemans J, van de Loo-Neus G, Buitelaar JK, Hoekstra PJ. Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatry. 2019;176(9):754\u201362.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1263_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jaac.2014.01.017","volume":"53","author":"DR Coghill","year":"2014","unstructured":"Coghill DR, Caballero B, Sorooshian S, Civil R, Rana P, Kaplan A, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a randomized-withdrawal study. J Am Acad Child Adolesc Psychiatry. 2014;53(6):647-57.e1.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"1263_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00213-015-4099-3","volume":"233","author":"R Cunill","year":"2016","unstructured":"Cunill R, Castells X, Tobias A, Capell\u00e0 D. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology. 2016;233(2):187\u201397.","journal-title":"Psychopharmacology"},{"issue":"10","key":"1263_CR22","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1177\/1087054720903372","volume":"25","author":"X Castells","year":"2021","unstructured":"Castells X, Ramos-Quiroga JA, Rigau-Ratera E, Bosch R, Nogueira M, Vidal X, et al. Relationship between treatment duration and efficacy of pharmacological treatment for ADHD: a meta-analysis and meta-regression of 87 randomized controlled trials. J Atten Disord. 2021;25(10):1352\u201361.","journal-title":"J Atten Disord"},{"issue":"1","key":"1263_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpeds.2006.01.052","volume":"149","author":"TE Wilens","year":"2006","unstructured":"Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, et al. Long-term atomoxetine treatment in adolescents with ADHD. J Pediatr. 2006;149(1):112\u20139.","journal-title":"J Pediatr"},{"issue":"2","key":"1263_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/00004583-200102000-00013","volume":"40","author":"B Vitiello","year":"2001","unstructured":"Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40(2):188\u201396.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"1263_CR25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/CHI.0b013e3180686d63","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Hinshaw SP, Arnold LE, Pelham WE, Molina BS, Hechtman L, et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1003\u201314.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1263_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1263_CR27","unstructured":"National Heart, Lung, and Blood Institute (NHLBI). Study quality assessment tools. 2021. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 19 Aug 2025."},{"issue":"1","key":"1263_CR28","first-page":"107","volume":"23","author":"SM Winsberg","year":"1987","unstructured":"Winsberg SM, Kupietz S, Richardson E. Is there dose-dependent tolerance associated with chronic methylphenidate therapy in hyperactive children: oral dose and plasma considerations. Psychopharmacol Bull. 1987;23(1):107\u201310.","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"1263_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00004583-198803000-00018","volume":"27","author":"S Kupietz","year":"1988","unstructured":"Kupietz S, Richardson E, Winsberg BG. Effects of methylphenidate dosage in hyperactive reading-disabled children: II. Reading achievement. J Am Acad Child Adolesc Psychiatry. 1988;27(2):241\u20135.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"1263_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1939-0025.1941.tb05781.x","volume":"11","author":"C Bradley","year":"1941","unstructured":"Bradley C, Bowen M. Amphetamine (Benzedrine) therapy of children\u2019s behavior disorders. Am J Orthopsychiatry. 1941;11(1):92\u2013103.","journal-title":"Am J Orthopsychiatry"},{"key":"1263_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00405570","volume":"5","author":"DE Rosenberg","year":"1963","unstructured":"Rosenberg DE, Isbell H, Miner EJ, Logan CR. Observations on direct and cross tolerance with LSD and d-amphetamine in man. Psychopharmacologia. 1963;5:1\u201315.","journal-title":"Psychopharmacologia"},{"issue":"20","key":"1263_CR32","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1001\/jama.1976.03270260026021","volume":"236","author":"JE Ballard","year":"1976","unstructured":"Ballard JE, Sleator EK, Massey BH, Sprague RL. Cardiovascular responses of hyperactive children to methylphenidate. JAMA. 1976;236(20):2870\u20134.","journal-title":"JAMA"},{"issue":"3","key":"1263_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S1461145713001132","volume":"17","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, et al. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol. 2014;17(3):371\u201381.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"1263_CR34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.euroneuro.2017.08.435","volume":"27","author":"C Skoglund","year":"2017","unstructured":"Skoglund C, Brandt L, D\u2019Onofrio BM, Larsson H, Franck J. Methylphenidate doses in ADHD and comorbid substance use disorders. Eur Neuropsychopharmacol. 2017;27(11):1144\u201352.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"1263_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40272-022-00492-4","volume":"24","author":"G Masi","year":"2022","unstructured":"Masi G, Fantozzi P, Wasserman S, De Luca C, Sesso G, Berloffa S, et al. Acute tolerability of methylphenidate in treatment-na\u00efve children with ADHD: an analysis of naturalistically collected data from clinical practice. Paediatr Drugs. 2022;24(2):147\u201354.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"1263_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00004714-199602000-00012","volume":"16","author":"LH Brauer","year":"1996","unstructured":"Brauer LH, de Wit H. Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. J Clin Psychopharmacol. 1996;16(1):72\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1263_CR37","first-page":"207","volume":"4","author":"LL Greenhill","year":"2001","unstructured":"Greenhill LL, Rudolph G, Feldman B, Curran S, Puig-Antich J, Gardner R. Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. Int J Neuropsychopharmacol. 2001;4(3):207\u201315.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"1263_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/(SICI)1098-2396(19990315)31:4<302::AID-SYN9>3.0.CO;2-A","volume":"31","author":"LS Kegeles","year":"1999","unstructured":"Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, et al. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse. 1999;31(4):302\u20138.","journal-title":"Synapse"},{"issue":"2","key":"1263_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0091-3057(91)90301-H","volume":"38","author":"TH Kelly","year":"1991","unstructured":"Kelly TH, Foltin RW, Fischman MW. The effects of repeated amphetamine exposure on multiple measures of human behavior. Pharmacol Biochem Behav. 1991;38(2):417\u201326.","journal-title":"Pharmacol Biochem Behav"},{"key":"1263_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S0893-133X(01)00253-6","volume":"25","author":"KS Strakowski","year":"2001","unstructured":"Strakowski KS, Roseburg H, DelBello M, Adler C. Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology. 2001;25:548\u201354.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1263_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/WNL.35.3.343","volume":"35","author":"JF Leckman","year":"1985","unstructured":"Leckman JF, Harcherik DF, Ort SI, Shaywitz BA, Cohen DJ. Short- and long-term treatment of Tourette\u2019s syndrome with clonidine: a clinical perspective. Neurology. 1985;35(2):343\u201351.","journal-title":"Neurology"},{"issue":"1","key":"1263_CR42","first-page":"100","volume":"115","author":"DJ Safer","year":"1989","unstructured":"Safer DJ, Allen RP. Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children. J Pediatr. 1989;115(1):100\u20134.","journal-title":"J Pediatr"},{"issue":"1","key":"1263_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/01.jcp.0000106223.36344.df","volume":"24","author":"TE Wilens","year":"2004","unstructured":"Wilens TE, Biederman J, Lerner M, Hammerness P, Konow J, Upadhyaya H, et al. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with ADHD: results from a one-year follow-up study. J Clin Psychopharmacol. 2004;24(1):36\u201341.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1263_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1017\/S003329170500471X","volume":"36","author":"SV Faraone","year":"2006","unstructured":"Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159\u201365.","journal-title":"Psychol Med"},{"issue":"1","key":"1263_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1463-3","volume":"17","author":"MA Katzman","year":"2017","unstructured":"Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17(1):302.","journal-title":"BMC Psychiatry"},{"key":"1263_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102021","volume":"60","author":"LJ Norman","year":"2023","unstructured":"Norman LJ, Price J, Ahn K, Sudre G, Sharp W, Shaw P. Longitudinal trajectories of childhood and adolescent attention deficit hyperactivity disorder diagnoses in three cohorts. EClinicalMedicine. 2023;60:102021.","journal-title":"EClinicalMedicine"},{"key":"1263_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2261-12-41","volume":"12","author":"AN Westover","year":"2012","unstructured":"Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc Disord. 2012;12:41.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"1263_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1176\/appi.ajp.2011.10111705","volume":"169","author":"B Vitiello","year":"2012","unstructured":"Vitiello B, Elliott GR, Swanson JM, Arnold LE, Hechtman L, Abikoff H, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012;169(2):167\u201377.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1263_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2215-0366(23)00042-1","volume":"10","author":"KKC Man","year":"2023","unstructured":"Man KKC, H\u00e4ge A, Banaschewski T, Inglis SK, Buitelaar JK, Carucci S, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the ADDUCE study. Lancet Psychiatry. 2023;10(5):323\u201333.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1263_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","volume":"81","author":"L Zhang","year":"2024","unstructured":"Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D\u2019Onofrio BM, et al. Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiat. 2024;81(2):178\u201387.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"1263_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2215-0366(25)00062-8","volume":"12","author":"LC Farhat","year":"2025","unstructured":"Farhat LC, Yoon Y, Gal\u00e1n CA, Carlson GA, Miklowitz DJ, Fristad MA, et al. Comparative cardiovascular safety of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025;12(5):355\u201365.","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"1263_CR52","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40263-021-00848-3","volume":"35","author":"S Cortese","year":"2021","unstructured":"Cortese S, Newcorn JH, Coghill D. A practical, evidence-informed approach to managing stimulant-refractory ADHD. CNS Drugs. 2021;35(10):1035\u201351.","journal-title":"CNS Drugs"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01263-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:02:33Z","timestamp":1773489753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01263-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01263-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuele Cortese has declared reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, the Canadian AADHD Alliance Resource, the British Association of Psychopharmacology, Healthcare Convention and the CCM Group team for educational activity on ADHD, and has received honoraria from Medice. Samuele Cortese is an Editorial Board member of\n                      CNS Drugs\n                      . Samuele Cortese was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Valeria Parlatini is recipient of an NIHR Advanced Fellowship (NIHR305518). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. VP also received travel and fees reimbursement by Medice to attend Eunethydis 2025, not related to the present project.\u00a0Chris Smith\u00a0and Hollie Walker have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CS was responsible for data curation, investigation and writing (original draft); HW for data curation, investigation and writing (original draft); VP for project administration, methodology, resources, supervision and writing (original draft and review); SC for conceptualisation, methodology, supervision and writing (review). All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}